PAVmed Historical Financial Ratios
| PAVMZ Stock | USD 0.01 0.00 0.00% |
PAVmed Series is promptly reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 2.1 M, Stock Based Compensation To Revenue of 4.32, Capex To Depreciation of 0.0784 or Ev To Sales of 22.81 will help investors to properly organize and evaluate PAVmed Series Z financial condition quickly.
PAVmed |
About PAVmed Financial Ratios Analysis
PAVmed Series ZFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate PAVmed Series investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on PAVmed financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across PAVmed Series history.
PAVmed Series Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing PAVmed Series Z stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on PAVmed Series sales, a figure that is much harder to manipulate than other PAVmed Series Z multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is PAVmed Series Z dividend as a percentage of PAVmed Series stock price. PAVmed Series Z dividend yield is a measure of PAVmed Series stock productivity, which can be interpreted as interest rate earned on an PAVmed Series investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from PAVmed Series' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, PAVmed Series' ROIC is fairly stable compared to the past year. Inventory Turnover is likely to rise to 12.51 in 2024, whereas PTB Ratio is likely to drop (0.58) in 2024.
| 2010 | 2023 | 2024 (projected) | Dividend Yield | 3.31E-4 | 2.98E-4 | 2.65E-4 | Price To Sales Ratio | 381.38 | 12.15 | 11.54 |
PAVmed Series fundamentals Correlations
Click cells to compare fundamentals
PAVmed Series Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PAVmed Series fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (9.48) | 53.04 | 3.09 | (4.42) | (0.55) | (0.58) | |
| Book Value Per Share | (2.3) | (0.15) | 15.37 | 1.84 | (3.32) | (3.16) | |
| Free Cash Flow Yield | (0.41) | (0.37) | (0.22) | (1.7) | (1.75) | (1.67) | |
| Operating Cash Flow Per Share | (6.63) | (6.93) | (7.85) | (11.95) | (7.2) | (7.56) | |
| Capex To Depreciation | 1.91 | 2.39 | 6.5 | 0.63 | 0.0825 | 0.0784 | |
| Pb Ratio | (9.48) | 53.04 | 3.09 | (4.42) | (0.55) | (0.58) | |
| Free Cash Flow Per Share | (6.65) | (6.95) | (8.14) | (12.21) | (7.23) | (7.59) | |
| Roic | (3.06) | (1.3) | (0.79) | (3.72) | 7.14 | 7.5 | |
| Net Income Per Share | (7.91) | (10.86) | (9.74) | (17.06) | (8.87) | (9.32) | |
| Payables Turnover | 0.006046 | 0.007755 | 0.18 | 1.34 | 3.59 | 3.77 | |
| Cash Per Share | 3.11 | 5.54 | 15.34 | 7.2 | 2.72 | 3.54 | |
| Pocfratio | (2.44) | (2.71) | (4.59) | (4.7) | (0.6) | (0.57) | |
| Interest Coverage | (4.42) | (437.61) | (440.58) | (71.48) | (116.8) | (122.64) | |
| Capex To Operating Cash Flow | (0.002037) | (0.00251) | (0.0362) | (0.0217) | (0.004651) | (0.004883) | |
| Pfcf Ratio | (2.71) | (4.58) | (4.53) | (0.59) | (0.57) | (0.6) | |
| Days Payables Outstanding | 60.4K | 47.1K | 2.1K | 273.09 | 101.54 | 96.46 | |
| Income Quality | 0.48 | 0.77 | 0.61 | 0.72 | 0.81 | 0.51 | |
| Roe | 4.17 | (18.11) | (0.82) | 10.46 | 1.19 | 1.13 | |
| Ev To Operating Cash Flow | (2.86) | (4.48) | (2.79) | (0.56) | (1.13) | (1.19) | |
| Pe Ratio | (2.27) | (2.93) | (3.79) | (0.42) | (0.46) | (0.49) | |
| Return On Tangible Assets | (2.2) | (1.74) | (0.59) | (2.0) | (2.02) | (2.13) | |
| Ev To Free Cash Flow | (2.85) | (4.47) | (2.7) | (0.55) | (1.13) | (1.18) | |
| Earnings Yield | (0.44) | (0.34) | (0.26) | (2.37) | (2.15) | (2.05) | |
| Net Debt To E B I T D A | (0.12) | 0.0641 | 1.38 | 0.0313 | (0.38) | (0.36) | |
| Current Ratio | 0.55 | 0.95 | 10.93 | 1.07 | 0.45 | 0.43 | |
| Tangible Book Value Per Share | (2.3) | (0.15) | 14.98 | 1.26 | (3.52) | (3.34) | |
| Graham Number | 18.39 | 12.1 | 51.14 | 25.01 | 38.55 | 40.48 | |
| Shareholders Equity Per Share | (1.9) | 0.6 | 11.93 | (1.63) | (7.44) | (7.07) | |
| Debt To Equity | (3.41) | (2.13) | 8.05 | (3.48) | (0.82) | (0.78) | |
| Capex Per Share | 0.0135 | 0.0174 | 0.28 | 0.26 | 0.0335 | 0.0657 | |
| Graham Net Net | (2.79) | (0.73) | 14.35 | (0.0259) | (5.14) | (4.88) | |
| Interest Debt Per Share | 6.93 | 4.06 | 4.84 | 5.88 | 6.19 | 4.12 | |
| Debt To Assets | 0.93 | 1.12 | 0.77 | 0.62 | 1.33 | 1.09 | |
| Enterprise Value Over E B I T D A | (2.29) | (2.74) | (2.03) | (0.4) | (0.78) | (0.82) | |
| Price Earnings Ratio | (2.27) | (2.93) | (3.79) | (0.42) | (0.46) | (0.49) | |
| Price Book Value Ratio | (9.48) | 53.04 | 3.09 | (4.42) | (0.55) | (0.58) | |
| Price Earnings To Growth Ratio | 0.0665 | (0.0929) | 0.37 | (0.007909) | 0.0119 | 0.0125 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.